AXNX Axonics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AXNX

Price (delayed)

$66.84

Market cap

$3.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.12

Enterprise value

$3.32B

Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of Bulkamid®, offers ...

Highlights
AXNX's EPS has soared by 91% year-on-year and by 48% since the previous quarter
The net income has soared by 90% YoY and by 49% from the previous quarter
AXNX's quick ratio is up by 47% year-on-year but it is down by 18% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.axonicsmodulation.com
Peers: OBIO OM

Key stats

What are the main financial stats of AXNX
Market
Shares outstanding
51M
Market cap
$3.41B
Enterprise value
$3.32B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.31
Price to sales (P/S)
8.95
EV/EBIT
N/A
EV/EBITDA
1,064.17
EV/Sales
9.06
Earnings
Revenue
$366.38M
EBIT
-$9.37M
EBITDA
$3.12M
Free cash flow
-$5.57M
Per share
EPS
-$0.12
Free cash flow per share
-$0.11
Book value per share
$12.58
Revenue per share
$7.46
TBVPS
$10.98
Balance sheet
Total assets
$719.92M
Total liabilities
$82.36M
Debt
$27.62M
Equity
$637.56M
Working capital
$445.61M
Liquidity
Debt to equity
0.04
Current ratio
10.73
Quick ratio
9.06
Net debt/EBITDA
-28.83
Margins
EBITDA margin
0.9%
Gross margin
74.9%
Net margin
-1.7%
Operating margin
-7.1%
Efficiency
Return on assets
-0.9%
Return on equity
-1%
Return on invested capital
-3.2%
Return on capital employed
-1.4%
Return on sales
-2.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXNX stock price

How has the Axonics stock price performed over time
Intraday
-0.16%
1 week
-0.73%
1 month
-2.08%
1 year
11.01%
YTD
7.41%
QTD
-3.09%

Financial performance

How have Axonics's revenue and profit performed over time
Revenue
$366.38M
Gross profit
$274.55M
Operating income
-$26.06M
Net income
-$6.09M
Gross margin
74.9%
Net margin
-1.7%
The company's net margin has surged by 92% YoY and by 51% QoQ
The net income has soared by 90% YoY and by 49% from the previous quarter
The operating margin has surged by 70% year-on-year and by 21% since the previous quarter
The company's operating income has surged by 60% YoY and by 15% QoQ

Growth

What is Axonics's growth rate over time

Valuation

What is Axonics stock price valuation
P/E
N/A
P/B
5.31
P/S
8.95
EV/EBIT
N/A
EV/EBITDA
1,064.17
EV/Sales
9.06
AXNX's EPS has soared by 91% year-on-year and by 48% since the previous quarter
The P/B is 15% above the last 4 quarters average of 4.6 but 10% below the 5-year quarterly average of 5.9
AXNX's equity is up by 12% year-on-year and by 4.4% since the previous quarter
The price to sales (P/S) is 79% lower than the 5-year quarterly average of 43.2 but 8% higher than the last 4 quarters average of 8.3
The revenue has increased by 34% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is Axonics business performance
AXNX's ROIC has soared by 93% YoY and by 45% QoQ
The ROE has soared by 92% YoY and by 50% from the previous quarter
AXNX's ROA has soared by 91% YoY and by 50% from the previous quarter
AXNX's ROS has soared by 88% year-on-year and by 37% since the previous quarter

Dividends

What is AXNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXNX.

Financial health

How did Axonics financials performed over time
The total liabilities has surged by 64% since the previous quarter but it has declined by 8% year-on-year
Axonics's current ratio has soared by 50% YoY but it has decreased by 20% from the previous quarter
The company's debt is 96% lower than its equity
AXNX's debt to equity has soared by 100% year-on-year
AXNX's equity is up by 12% year-on-year and by 4.4% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.